Novo Nordisk

Novo Nordisk aims to launch five new blockbuster drugs by 2030 and reach $23 billion in annual revenue by 2035, facing rising competition from Eli Lilly and generic alternatives.

Novo Nordisk has canceled two clinical trials for cardiovascular drugs after disappointing results, dealing a direct blow to its strategy to expand beyond weight-loss treatments.

Three years ago, Novo Nordisk ruled the market with an iron hand, but Eli Lilly has made a massive overtake. The pill revolution, price drops in the USA, and a lawsuit — the drama behind a market worth hundreds of billions.